IBRX icon

ImmunityBio

2.84 USD
At close May 16, 4:00 PM EDT
After hours
2.81
-0.03
1.06%
1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
-41.20%
10 years
-91.80%
 

About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Employees: 680

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

120% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 20

71% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 41

11% more funds holding

Funds holding: 180 [Q3] → 199 (+19) [Q4]

1.45% more ownership

Funds ownership: 9.86% [Q3] → 11.32% (+1.45%) [Q4]

17% less call options, than puts

Call options by funds: $8.21M | Put options by funds: $9.86M

17% less capital invested

Capital invested by funds: $256M [Q3] → $212M (-$43.8M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$8
182%
upside
Avg. target
$15.33
440%
upside
High target
$30
956%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andres Maldonado
19% 1-year accuracy
10 / 52 met price target
182%upside
$8
Buy
Reiterated
12 May 2025
D. Boral Capital
Jason Kolbert
22% 1-year accuracy
89 / 402 met price target
956%upside
$30
Buy
Maintained
12 May 2025
HC Wainwright & Co.
Andrew Fein
29% 1-year accuracy
98 / 337 met price target
182%upside
$8
Buy
Reiterated
28 Apr 2025

Financial journalist opinion

Based on 10 articles about IBRX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
Negative
Zacks Investment Research
5 days ago
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago.
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Neutral
Business Wire
5 days ago
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the first-quarter ended March 31, 2025. With the issuance of the permanent J-code (J9028) in January 2025, ImmunityBio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter, with March.
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
Positive
Seeking Alpha
1 week ago
ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA
ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX shares to around $2.00, but the trading volume was not extremely high. Despite the setback, I maintain a conviction level of 3 out of 5 for IBRX, focusing on potential long-term gains and upcoming catalysts.
ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA
Negative
Benzinga
1 week ago
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
Neutral
Business Wire
1 week ago
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease. This RTF letter was received despite reaching unanimous.
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
Negative
Zacks Investment Research
2 weeks ago
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Negative
Seeking Alpha
2 weeks ago
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings.
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Neutral
Business Wire
2 weeks ago
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced positive long-term results from its QUILT-3.032 study of ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease. The findings were shared during an oral presentation at the American Urological.
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
Neutral
Business Wire
3 weeks ago
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) and updated data on papillary disease without CIS at the American Urological Association Annual Meeting (AUA 2025) in Las Vegas, April 26-29. The company will also host an educational and peer-networking event to discuss ImmunityBio's approa.
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
Charts implemented using Lightweight Charts™